A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT05512390 · RECRUITING
Trial details
- NCT number
- NCT05512390
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-26
- Primary completion
- 2027-02-01
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.